Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
14.09
-0.22 (-1.54%)
At close: Feb 11, 2026, 4:00 PM EST
14.20
+0.11 (0.78%)
After-hours: Feb 11, 2026, 5:56 PM EST
Seres Therapeutics Employees
Seres Therapeutics had 103 employees as of December 31, 2024. The number of employees decreased by 130 or -55.79% compared to the previous year.
Employees
103
Change (1Y)
-130
Growth (1Y)
-55.79%
Revenue / Employee
$3,408
Profits / Employee
$52,369
Market Cap
127.47M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103 | -130 | -55.79% |
| Dec 31, 2023 | 233 | -198 | -45.94% |
| Dec 31, 2022 | 431 | 98 | 29.43% |
| Dec 31, 2021 | 333 | 178 | 114.84% |
| Dec 31, 2020 | 155 | 47 | 43.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 279 |
| Fate Therapeutics | 181 |
| Vaxart | 105 |
| Korro Bio | 87 |
| ALX Oncology Holdings | 44 |
| Spero Therapeutics | 32 |
| Black Diamond Therapeutics | 24 |
| Unicycive Therapeutics | 23 |
MCRB News
- 5 weeks ago - Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy - GlobeNewsWire
- 2 months ago - Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - GlobeNewsWire
- 3 months ago - Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 - GlobeNewsWire
- 3 months ago - Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 - GlobeNewsWire
- 4 months ago - Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant - GlobeNewsWire
- 5 months ago - Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway - GlobeNewsWire